Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)

Core Insights - Sanuwave Health, Inc. reported preliminary revenues of $10.1 million to $10.2 million for Q2 2025, marking the highest quarterly revenues in the company's history [1][2] - The revenue for Q2 2025 reflects an increase of 41% to 42% compared to Q2 2024, while the first half of 2025 saw a revenue increase of 50% to 51% compared to the first half of 2024 [1][2] Company Developments - The CEO highlighted that the first half of 2025 has been a transition period for the company, with the addition of a new head of sales and a new head of commercial operations [3] - The company is expanding its sales team, reaching 13 salespeople and covering all national sales territories for the first time under the current CEO [3] - A national accounts manager has been added to pursue larger market opportunities, indicating a strategic focus on growth [3] Future Outlook - The company plans to release full Q2 results around August 8, 2025, providing a more comprehensive update on performance and future plans [3] - Sanuwave is focused on the research, development, and commercialization of patented, non-invasive medical systems aimed at tissue repair and regeneration [4] - The company's portfolio includes regenerative medicine products that support normal healing processes across various medical conditions [5]